A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Octapharma

Status and phase

Completed

Phase 1

Conditions

Comparison of Octaplas LG and Octaplas SD

Treatments

Biological: Octaplas LG

Biological: Octaplas SD

Study type

Interventional

Funder types

Industry

Identifiers

NCT01063595

LAS-203

Details and patient eligibility

About

The primary objective of the study was to compare the efficacy of Octaplas LG with Octaplas SD in terms of recovery of coagulation factors and other haemostatic parameters. The secondary objective of the study was to compare the safety and tolerability of Octaplas LG with Octaplas SD in terms of haematological and clinical chemistry parameters and adverse event monitoring.

Enrollment

63 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Capable of understanding and complying with all aspects of the protocol.
Signed Informed Consent.
Capable of understanding the plasmapheresis information sheet and sign it.
Healthy male or female volunteers, age 18 years or older.
Women must have negative pregnancy test (human chorionic gonadotropin [HCG] based assay).
Women must have sufficient methods of contraception (eg, intrauterine device, oral contraception, etc).
No clinically relevant abnormalities in medical history and general physical examination.
Standard health insurance.

Exclusion criteria

Pregnancy or lactation.
Tattoos within the last 3 months.
Subject was treated therapeutically with fresh frozen plasma, blood, or plasma-derived products within the last 6 months.
Hypersensitivity to blood products or plasma proteins.
History of angioedema.
History of coagulation or bleeding disorder or any other known abnormality affecting coagulation, fibrinolysis, or platelet function.
Any clinically significant abnormal laboratory values.
IgA deficiency.
Seropositivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus type 1 or type 2 antibodies.
Symptoms of a clinically relevant illness within 3 weeks before the first trial day.
History of or suspected drug or alcohol abuse.
Subjects currently participating in another clinical study.
Any investigational medicinal product administration within the last 4 weeks.